The role of programed death-ligand 1 in renal diseases. (3rd July 2020)

• Record Type: Journal Article
• Authors: Wei, Yi; Jiang, Zongpei
• Is Part Of: Journal of receptor and signal transduction research. Volume 40:Number 4(2020)
• Page Start: 295
• Page End: 300
• Publication Date: 2020-07-03
• Subjects: PD-L1 -- renal disease -- lupus nephritis -- acute kidney injury -- immunotherapy; Cell receptors -- Periodicals; Cellular signal transduction -- Periodicals; 571.6
• DOI: 10.1080/10799893.2020.1734820
• Languages: English
• ISSNs: 1079-9893

Abstract

Abstract: Programed death-ligand 1 (PD-L1, B7-H1, CD274) is a coinhibitory molecule that plays a vital role in the pathogenesis of both neoplastic and nonneoplastic diseases. However, the role of PD-L1 in primary and secondary renal diseases remains to be clarified. Previous studies have shown that both intracellular and intercellular PD-L1 participate in renal diseases via complex mechanisms. PD-L1 plays a dual role in lupus nephritis and has a protective effect in renal ischemia reperfusion injury and nephrotoxic nephritis but not in proliferative immune complex glomerulonephritis. PD-L1 supplementation, anti-PD-L1 antibodies, and D-peptide antagonists have promising application prospects in the treatment of renal diseases. In this review, we summarize the available data published on PD-L1 in renal diseases for the first time.